Fierce Biotech April 24, 2024
The handheld ultrasound developer Exo has launched two new FDA-cleared artificial intelligence applications tied to its pocket-sized Iris probe, which made its own debut last fall.
The latest green lights add cardiac and lung-focused programs to the company’s bladder, hip and thyroid scanning options—to offer automatic estimations of a patient’s heart ejection fraction at the point-of-care, as well as image capture guidance for catching the signs of pneumonia or pulmonary edema.
“It’s time for a reimagined approach to addressing heart failure at scale,” Exo co-founder and CEO Sandeep Akkaraju said in a statement. “That’s why Exo is putting AI-empowered medical imaging in the hands of every caregiver, no matter their specialty.”
In addition, the smartphone-connected Iris now features pulsed-wave Doppler...
Today's Sponsors
Today's Sponsor